Drug Profile
Research programme: erythropoietin mimetics - BioRexis
Alternative Names: EPO mimetic - BioRexis; EPO peptide mimetic - BioRexis; EPO receptor agonist peptide; Erythropoietin mimetics - BioRexisLatest Information Update: 21 May 2007
Price :
$50
*
At a glance
- Originator BioRexis Pharmaceutical Corporation
- Class
- Mechanism of Action Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 21 Apr 2007 No development reported - Preclinical for Anaemia in USA (unspecified route)
- 14 Jul 2004 The programme is available for licensing (http://www.biorexis.com)
- 14 Jul 2004 Preclinical trials in Anaemia in USA (unspecified route)